Results 161 to 170 of about 26,593 (244)

Effects of Targeted Radionuclide Therapy on Cancer Cells Beyond the Ablative Radiation Dose. [PDF]

Int J Mol Sci
Ferro-Flores G, Azorín-Vega E, Ocampo-García B, Luna-Gutiérrez M, Cruz-Nova P, Meléndez-Alafort L.   +5 more
europepmc   +1 more source

An Engineered Probiotic Platform for Cancer Epitope-Independent Targeted Radionuclide Therapy of Solid Tumors. [PDF]

Adv Healthc Mater, 2023
Siddiqui NA, Ventrola AJ, Hartman AR, Konare T, Kamble NS, Thomas SC, Madaan T, Kharofa J, Sertorio MG, Kotagiri N.   +9 more
europepmc   +1 more source

Development of a Novel Engineered Antibody Format for PSMA-Targeted Radionuclide Therapy. [PDF]

Mol Pharm
Fletcher NL, Houston ZH, Chandler PG, Yan E, Holgate R, Wheatcroft M, Thurecht KJ.   +6 more
europepmc   +1 more source

Radiobiological Assessment of Targeted Radionuclide Therapy with [¹⁷⁷Lu]Lu-PSMA-I&T in 2D vs. 3D Cell Culture Models. [PDF]

Int J Mol Sci, 2023
Raitanen J, Barta B, Fuchs H, Hacker M, Balber T, Georg D, Mitterhauser M.   +6 more
europepmc   +1 more source

Outcome and safety of single-dose docetaxel-augmented targeted radionuclide therapy using [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in treatment-refractory mCRPC: preliminary evidence from a pilot experience. [PDF]

EJNMMI Res
Ebert N, Rosar F, Burgard C, Bartholomä M, Maus S, Hein C, Blickle A, Ezziddin S, Khreish F.   +8 more
europepmc   +1 more source

¹³¹I-Labeled Anti-HER2 Nanobody for Targeted Radionuclide Therapy of HER2-Positive Breast Cancer. [PDF]

Int J Nanomedicine, 2023
Zhao L, Gong J, Qi Q, Liu C, Su H, Xing Y, Zhao J.   +6 more
europepmc   +1 more source

Recommendations for reporting preclinical radiobiological studies in targeted radionuclide therapy. [PDF]

Eur J Nucl Med Mol Imaging
Mendes F, Terry SYA, Spiegelberg D, Cornelissen B, Bolcaen J, Nonnekens J, European Working group of Radiobiology of Molecular Radionuclide Therapy.   +6 more
europepmc   +1 more source

Tumor sink effect on melanin-ligand [¹³¹I]ICF01012 in melanoma and its implications for targeted radionuclide therapy. [PDF]

EJNMMI Res
Jouberton E, Besse S, Billoux T, Auzeloux P, Schmitt S, Chezal JM, Sas N, Noirault L, Auriol M, Levesque S, Delmas M, Chaussin B, Chautard E, Miot-Noirault E, Rouanet J, Cachin F.   +15 more
europepmc   +1 more source

Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment. [PDF]

Clin Cancer Res, 2022
Kleinendorst SC, Oosterwijk E, Bussink J, Westdorp H, Konijnenberg MW, Heskamp S.   +5 more
europepmc   +1 more source

Relevance and implementation of patient-specific dosimetry in targeted radionuclide therapy

BIO Web of Conferences, 2019
Bardiès Manuel
doaj   +1 more source